The tip of the iceberg: predicting PARP inhibitor efficacy in prostate cancer

Lancet Oncol. 2020 Jan;21(1):17-19. doi: 10.1016/S1470-2045(19)30780-6. Epub 2019 Dec 2.

Authors

Silke Gillessen¹, Robert G Bristow²

Affiliations

¹ Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Università della Svizzera italiana, Lugano, Switzerland; Division of Cancer Sciences, University of Manchester, Manchester, UK. Electronic address: silke.gillessen@eoc.ch.
² Division of Cancer Sciences, University of Manchester, Manchester, UK; Translational Oncogenomics, Cancer Research UK Manchester Institute and Manchester Cancer Research Centre, Manchester, UK.

PMID: 31806542
DOI: 10.1016/S1470-2045(19)30780-6

No abstract available

Publication types

Comment

MeSH terms

DNA Repair
Humans
Male
Phthalazines
Piperazines
Poly(ADP-ribose) Polymerase Inhibitors*
Prostatic Neoplasms, Castration-Resistant*

Substances

Phthalazines
Piperazines
Poly(ADP-ribose) Polymerase Inhibitors
olaparib